Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

50 results about "Placebo" patented technology

A placebo (/pləˈsiːboʊ/ plə-SEE-boh) is an inert substance or treatment which is designed to have no therapeutic value. Common placebos include inert tablets (like sugar pills), inert injections (like saline), sham surgery, and other procedures.

Method for evaluating curative effect of compound glutamine enteric capsule

InactiveCN119074964AAccurate evaluationScientifically assisted preventive medicationMicrobiological testing/measurementAnalysis using nuclear magnetic resonanceSecondary PreventionsTherapeutic evaluation
The invention is applicable to the technical field of evaluation of curative effects of compound glutamine enteric capsules, and provides a method for evaluating the curative effects of compound glutamine enteric capsules, which comprises the following steps: S1, establishing a first-level prevention inclusion standard and a second-level prevention inclusion standard; s2, the patients meeting the first-grade prevention inclusion standard are randomly divided into a group A and a group B according to the proportion of 1: 1, the group A takes the compound glutamine enteric capsule and then takes the placebo, the group B takes the placebo and then takes the compound glutamine enteric capsule, and each group is compared before and after; s3, the patients meeting the secondary prevention inclusion standard are randomly divided into a group C and a group D according to the proportion of 1: 1, the group C is a compound glutamine enteric capsule group, and the group D is a placebo group; and S4, setting an observation terminal point and an observation index, performing curative effect evaluation, and performing statistics, processing and analysis on data. In the scheme, the first-stage prevention adopts a cross test design, and the second-stage prevention adopts a parallel contrast design, so that the curative effect of the compound glutamine enteric capsule can be evaluated more accurately.
Owner:DIAO GRP CHENGDU PHARMA

Cough and asthma relieving compound medicine for nebulization treatment of respiratory system as well as preparation and application of cough and asthma relieving compound medicine

The invention provides a cough and asthma relieving compound medicine for nebulization treatment of a respiratory system as well as preparation and application of the cough and asthma relieving compound medicine. The cough and asthma relieving compound medicine takes various traditional Chinese medicinal materials such as ginkgo and ephedra as main raw materials, and further comprises compound bacteria, an osmotic pressure regulator and a cosolvent. The compound bacteria are prepared from cordyceps sinensis, bamboo fungus and pine olive in a specific mass ratio, the osmotic pressure regulator is prepared from glucose and glycerol in a specific ratio, and the cosolvent has multiple selectable components. The preparation method comprises a plurality of steps and unique processes including medicinal material extraction, salifying modification, ultrasonic extraction and the like. Clinical tests show that compared with a control group and a placebo group, the compound medicine disclosed by the invention can remarkably improve lung function related indexes of patients and reduce the level of inflammatory factors, and a visual simulation scoring method also proves that the compound medicine can effectively relieve symptoms of cough and asthma. The medicine can be used for preparing aerosol inhalation medicines for treating various respiratory diseases such as bronchial asthma and chronic obstructive pulmonary diseases, and has a good application prospect.
Owner:GUANGDONG PROVINCIAL HOSPITAL OF TRADITIONAL CHINESE MEDICINE HAINAN HOSPITAL

Traditional Chinese medicine granule placebo and preparation method thereof

The invention belongs to the technical field of traditional Chinese medicine particle placebo preparation, and discloses a traditional Chinese medicine particle placebo which is prepared from a medicine water extract and a medicine residue water extract. The preparation method of the medicine water extract comprises the following steps: decocting the traditional Chinese medicine raw materials twice, concentrating to obtain clear paste, carrying out alcohol precipitation, standing, filtering, and concentrating filtrate to obtain the medicine water extract. The preparation method of the decoction dreg water extract comprises the following steps: drying and frying filter residues, adding water for decoction, filtering, and concentrating filtrate. The content of the active ingredients in the traditional Chinese medicine granule placebo is lower than 10wt% of the content of the active ingredients in the corresponding medicine, and the smell is similar to that of the corresponding medicine. And the preparation process is simple and easy to industrialize.
Owner:SINOPHARM ZHONGLIAN PHARMA CO LTD

Method for testing non-inferior performance of new medicine when curative effect data obeys partial normal distribution

The invention discloses a method for testing the non-inferior performance of a new drug when curative effect data obeys partial normal distribution, aiming at the condition that the curative effect data obeys partial normal distribution, the non-inferior performance of the new drug is tested so as to determine the non-inferior performance of the new drug relative to a standard drug, and meanwhile, the reliability of a detection result is ensured. The method comprises the following steps: S1, acquiring drug curative effect data in clinical tests: in a three-arm non-inferior clinical test, based on drug curative effect indexes, respectively acquiring drug curative effect data of three groups of clinical test results of a new drug group, a standard drug control group and a placebo control group, the curative effect data obeying partial normal distribution; s2, probability calculation of first-class errors: in the three-arm non-inferior hypothesis test model, a frequency method or a Bayesian method is used to calculate the drug curative effect data of the three groups of test results to obtain the probability of first-class errors, and the probability of first-class errors is the probability of occurrence of a standby hypothesis H1 when an original hypothesis H0 is established; and S3, non-inferior determination of the new drug: if the probability of making the first type of errors is greater than a given reference value, determining that the new drug has non-inferior relative to the standard drug, and the reference value is a critical value which is given in advance and has clinical significance.
Owner:KUNMING UNIV OF SCI & TECH

Use of tetramethylpyrazine nitrone derivative in prevention or treatment of type 2 diabetes

PCT designated stage expiredWO2024243951A1Organic active ingredientsMetabolism disorderHba1c levelPharmaceutical Substances
The present invention provides a use of a tetramethylpyrazine nitrone (TBN) derivative in preparation of drugs and in prevention or treatment of type 2 diabetes. Clinical tests show that compared with placebos, a TBN derivative can obviously reduce blood sugar and glycosylated hemoglobin levels in patients with type 2 diabetes.
Owner:GUANGZHOU MAGPIE PHARMA

Acupoint sticking traditional Chinese medicine composition with effect of treating irritable bowel syndrome, acupoint patch and preparation method and application thereof

PendingCN122624615ADiseaseEfficacy
The application discloses a point application traditional Chinese medicine composition with an effect of treating irritable bowel syndrome, a point application plaster and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The application provides a point application traditional Chinese medicine composition and a point application plaster. The traditional Chinese medicine composition comprises the following components: psoralea, radix codonopsis, dried zedoary, fried atractylodes, mace, schisandra chinensis and evodia. The composition is prepared according to the principle of less medicine and special function and treatment of disease and seeking the origin. The core tonifying medicine, psoralea, dried zedoary and radix codonopsis, has a prominent dosage proportion and remarkable effects of warming the spleen and kidney yang and invigorating the spleen and replenishing qi. The application finds through clinical research that the clinical total effective rate of the test group is 76.7%, the curative effect is accurate and better than that of a placebo, the IBS-SSS score, the TCM syndrome score and the stool character score of IBS patients can be reduced, the symptoms of the patients are improved, and the composition can effectively treat IBS.
Owner:DONGFANG HOSPITAL BEIJING UNIV OF CHINESE MEDICINE

Masturbation matrix composition for simulating bitter taste after traditional Chinese medicine decoction, modified rheum officinale and coptis chinensis gargle masturbation and preparation method thereof

The invention provides an application of combined use of xanthan gum, soya bean lecithin and a bitter agent in a bitter placebo matrix used in a traditional Chinese medicine decoction. The invention provides a placebo matrix composition capable of simulating the aftertaste of a traditional Chinese medicine decoction. The decoction comprises the following raw materials in percentage by weight: 0.03-0.04% of a bitterness agent, 0.05-0.2% of xanthan gum and 1.5-3% of soybean lecithin. The invention further provides the modified rheum officinale and coptis chinensis gargle placebo. Aiming at the defects that only instantaneous bitter taste can be generated by simply adding a bitterness agent and the bitter taste fades quickly in the prior art, the invention provides a method capable of actively regulating and remarkably prolonging the bitter taste sensing duration, so that the placebo can realistically reproduce a complete time-intensity curve of'bitter taste in mouth-lasting bitter taste after mouth 'of a traditional Chinese medicine decoction; therefore, the testee is prevented from being broken by bitterness lasting time difference. The method breaks through the limitation of traditional solution simulation, and aims to provide a new thought for preparation of traditional Chinese medicine placebo, further improve the sensory simulation level of the placebo and provide a method and reference for research of similar placebo.
Owner:CHENGDU UNIV OF TRADITIONAL CHINESE MEDICINE

Blinding device for injecting devices

Blinding Device for Injection Devices In one aspect the present disclosure relates to a blinding device (50) for concealing an injection device (1) in clinical trials, wherein the injection device (1) comprises a movable plunger (20) and an elongated barrel (10) extending in a longitudinal direction (2, 3) and filled with a medicament (8) or with a placebo, wherein the plunger (20) is longitudinally movable relative to the barrel (10) for expelling the medicament (8) or the placebo from the barrel (10) and wherein the injection device (1) comprises a flange portion (17, 18) at or near a proximal end of the barrel (10), the blinding device (50) comprising: - an opaque housing (52) to cover the barrel (10) and the plunger (20), the opaque housing (60) comprising: - a barrel cover portion (54) to receive and to cover the barrel (10), - a plunger cover portion (56) of variable longitudinal extent to receive and to cover the plunger (20), and - a housing flange portion (55) protruding outwardly from the barrel cover portion (54), wherein the housing flange portion (55) comprises a first flange part (61) and a second flange part (62), which are mutually connectable to form a flange assembly (66) connecting the barrel cover portion (54) with the plunger cover portion (56). (Fig. 1)
Owner:SANOFI SA(FR)

Devices and methods for precision dose delivery

PendingUS20260192054A1Pharmacy medicineDose delivery
Disclosed herein are delivery devices for delivering a volume of a drug product, placebo product, or other product including a fluid. The devices may include a barrel having a longitudinal axis, a proximal end region, and a distal end region. The proximal end region may include an opening, and the barrel may be configured to receive a drug therein. A plunger rod may be disposed at least partially inside the barrel and protruding from the opening. The plunger rod may include a rack having a plurality of teeth. The device may further include a pinion having a plurality of teeth configured to engage with the plurality of teeth of the rack, and rotation of the pinion against the rack may move at least a part of the plunger rod along the longitudinal axis of the barrel.
Owner:REGENERON PHARMACEUTICALS INC

Treatment and prevention of sepsis or other dysregulated inflammatory responses using CETP inhibitor obicetrapib

PCT designated stageWO2026087915A1Organic active ingredientsAntipyreticPlaceboIncreased hdl
This invention relates to methods and compositions useful in subjects suffering from or at risk of suffering from sepsis or other dysregulated inflammatory responses. It has been demonstrated that the CETP inhibitor obicetrapib not only preserved or increased HDL-C and Apo A1 levels, but also reduced an important pro-inflammatory marker, IL-1β, and significantly increased survival, relative to placebo, in a suitable sepsis mouse model. Thus, broadly stated, the present invention concerns the use of CETP inhibitors in the prevention, treatment, management or amelioration of sepsis, or other dysregulated inflammatory responses in a subject.
Owner:NEWAMSTERDAM PHARMA BV

Traditional Chinese medicine composition for treating cerebral hemorrhage and application thereof

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating cerebral hemorrhage and application thereof. The traditional Chinese medicine composition comprises the following main active components in parts by mass: 10-30 parts of red ginseng, 10-20 parts of rheum officinale, 0.5-1 part of processed semen strychni, 1-10 parts of leech and 10-30 parts of pseudo-ginseng. Clinical tests show that 24 hours after cerebral hemorrhage attacks, the traditional Chinese medicine composition can obviously improve uw-mRS and mRS of cerebral hemorrhage patients for 90 days, obviously improve the poor prognosis of the cerebral hemorrhage patients and improve the independent living ability. Meanwhile, compared with a placebo group, the traditional Chinese medicine compound group for treating related adverse events has no significant difference (Pgt; 0.05), which indicates that the traditional Chinese medicine composition disclosed by the invention is good in safety. The results show that the traditional Chinese medicine composition can effectively treat cerebral hemorrhage and is good in safety.
Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE

Use of PQQ in preparation of modulator for menstrual cycle disorders

PCT designated stage expiredWO2024245461A1Organic active ingredientsSexual disorderPlaceboMenstrual cycle disorder
Disclosed in the present invention is the use of PQQ in the preparation of a modulator for menstrual cycle disorders. Preliminary experimental data shows that oral PQQ has a significant effect of preventing, ameliorating or treating menstrual cycle disorders compared with a placebo.
Owner:GUANGZHOU HUTONGYOUWU BIOTECHNOLOGY CO LTD

Systems, methods and devices for generating and administering digital therapeutic placebos and shams

ActiveJP2024180435AMedical simulationMedical communicationCognitive behavioral therapyPlacebo
To provide a system for treating a disease or disorder.SOLUTION: A method of treatment via data processing hardware comprises: administering to a first set of one or more users, a digital therapeutic, where the digital therapeutic comprises at least cognitive behavioral therapy content; administering to a second set of one or more users, at least one of sham and placebo digital therapeutics; determining a first efficacy value based on an analysis of engagement of the first set with the digital therapeutic; determining a second efficacy value based on an analysis of engagement of the second set with the sham or placebo digital therapeutic; determining a third efficacy value associated with the digital therapeutic based on a comparison of the first and second efficacy values; altering the cognitive behavioral therapy content of the digital therapeutic based on the third efficacy value to provide an updated digital therapeutic; and administering the updated digital therapeutic to a third set of one or more users.SELECTED DRAWING: Figure 8
Owner:CLICK THERAPEUTICS INC

Early onset response, favorable tolerability, and side effect profile in the treatment of fibromyalgia

PendingUS20250322926A1Organic active ingredientsAntipyreticAverage diastolic blood pressureSide effect
The present disclosure provides methods for treating or managing fibromyalgia and its associated symptoms in a subject in need hereof characterized by an early onset of one or more of: (1) a reduction in widespread pain characterized by about 0.3 or more difference in the LS mean change in the NRS Pain Score; (2) a reduction in sleep disturbance characterized by about 2.9 or more difference in the LS Mean change in PROMIS Sleep Disturbance T-score; (3) a reduction in fatigue characterized by about 2.0 or more difference in the LS Mean change in PROMIS Fatigue T-score; or (4) an improved sleep quality characterized by about 0.5 or more difference in the LS Mean change in NRS Sleep Quality Score, each as compared to placebo, comprising administering to a subject in need thereof 2.8 mg or 5.6 mg cyclobenzaprine HCl once daily in one or more dosage units by transmucosal administration. The present disclosure also provides methods for preventing or avoiding one or more of a clinically meaningful change in mean weight, a clinically meaningful change in mean systolic blood pressure or mean diastolic blood pressure, or a decline in sexual functioning in conjunction with treating or managing fibromyalgia or its associated symptoms in a subject in need thereof, the treatment or management being characterized by the transmucosal administration of cyclobenzaprine HCl in one or more dosage units (e.g., a first dosage unit or a second dosage unit). The cyclobenzaprine HCl of these methods is in the form of a mannitol eutectic (e.g., a 75%±2% by weight cyclobenzaprine HCl and 25%±2% by weight β-mannitol eutectic) and the one or more dosage units further comprise a basifying agent.
Owner:TONIX PHARMA LTD

Experimental method for verifying curative effect of retinoic acid on schizophrenia

The invention provides an experimental method for verifying the curative effect of retinoic acid on schizophrenia, which comprises the following steps: step 1, selecting two groups of pregnant SD rats, injecting Poly I: C into tail veins of one group of SD rats after 9.5 days of pregnancy according to the standard of 10 mg / kg, and taking male offspring rats as schizophrenia model group rats; the other group of SD rats are intravenously injected with equal-volume normal saline at the tail after pregnancy 9.5 days, and the male offspring rats are the control group; 2, the model components are divided into two groups, retinoic acid is fed to one group 45 days after birth according to the standard of 3 mg / kg / day, an equal amount of placebo is injected to the other group, and an equal amount of placebo is injected to the control group; step 3, carrying out behavioral detection experiments on the three groups of rats in the step 2; and 4, implanting electrodes into hippocampal CA1 regions of the three groups of rats in the step 2, and recording and analyzing electroencephalogram activities of the three groups of rats. The experimental method provided by the invention proves that the retinoic acid has good application value in preparation of the schizophrenia medicine.
Owner:河南医药大学第二附属医院(河南省精神病医院)

Acupuncture auxiliary device

The utility model discloses a needling auxiliary device, and belongs to the technical field of needling auxiliary devices. The needling auxiliary device comprises a base assembly and a needling instrument assembly. The base assembly comprises a first transparent base and a second transparent base, peep-proof layers are arranged on the outer sides of the first transparent base and the second transparent base, a first through hole is formed in the first transparent base, and a second through hole is formed in the second transparent base; the needling instrument assembly comprises an acupuncture needle and a placebo needle, the acupuncture needle penetrates through the first through hole, and the placebo needle penetrates through the second through hole. According to the acupuncture auxiliary device, the treatment efficiency and effect of the acupuncture needle and the placebo needle are effectively improved, and the situation that a subject observes whether the acupuncture needle or the placebo needle is punctured into the acupuncture point or not, and consequently the accuracy of a test result is affected can be avoided.
Owner:GUANGZHOU UNIV OF CHINESE MEDICINE SHENZHEN HOSPITAL (FUTIAN)

Pharmaceutical analysis method based on biomics and application

The invention provides a pharmaceutical analysis method based on biomics and application, and belongs to the technical field of medical analysis. Comprising the following steps: S1, experiment grouping: screening participants according to a preset grouping standard, and randomly dividing the participants into a medicine group and a placebo group; s2, experimental process and sample collection: collecting detection samples of the drug group and the placebo group at three time nodes, namely before medication, during the experiment and after the experiment; s3, sample analysis; and S4, analyzing a metabolic pathway where the drug plays a role, and enriching metabolites and drug target genes. Through specific standard component grouping, sample collection in a preset stage and multi-omics comprehensive analysis, metabonomics and transcriptomics combined analysis is carried out on each experimental group, metabolism and transcription co-enrichment pathways are screened, and then metabolic pathways, enriched metabolites and drug target genes in which drugs play roles, and interaction relationships are analyzed. The potential mechanism of the medicine playing a role in relieving diseases is analyzed through a multi-omics combined technology, and reference is provided for follow-up medicine development and application.
Owner:BEIJING XIANYUN QIYUAN TECH CO LTD

Zervimesine for treating neurodegenerative disease

The present disclosure provides a method of treating or inducing cognitive preservation in a patient with Alzheimer's disease, comprising administering an effective amount of CT1812. The effective amount of CT1812 is 100 mg or 300 mg administered orally once daily. The method demonstrates improvements in cognitive outcomes compared to placebo across multiple measures including ADAS-Cog11, MMSE, ADCS-ADL, and ADCS-CGIC. The method demonstrates improvements in cognitive outcomes in patients with low plasma levels of phosphorylated tau 217 prior to administration.
Owner:COGNITION THERAPEUTICS INC

Cyclobenzaprine HCL for use in treating fibromyalgia with early onset response and favorable tolerability and side effect profile

PendingAU2024408589A1Average diastolic blood pressureSexual functioning
The present disclosure provides methods for treating or managing fibromyalgia and its associated symptoms in a subject in need hereof characterized by an early onset of one or more of: (1) a reduction in widespread pain characterized by about 0.3 or more difference in the LS mean change in the NRS Pain Score; (2) a reduction in sleep disturbance characterized by about 2.9 or more difference in the LS Mean change in PROMIS Sleep Disturbance T-score; (3) a reduction in fatigue characterized by about 2.0 or more difference in the LS Mean change in PROMIS Fatigue T-score; or (4) an improved sleep quality characterized by about 0.5 or more difference in the LS Mean change in NRS Sleep Quality Score, each as compared to placebo, comprising administering to a subject in need thereof 2.8 mg or 5.6 mg cyclobenzaprine HCl once daily in one or more dosage units by transmucosal administration. The present disclosure also provides methods for preventing or avoiding one or more of a clinically meaningful change in mean weight, a clinically meaningful change in mean systolic blood pressure or mean diastolic blood pressure, or a decline in sexual functioning in conjunction with treating or managing fibromyalgia or its associated symptoms in a subject in need thereof, the treatment or management being characterized by the transmucosal administration of cyclobenzaprine HCl in one or more dosage units (e.g., a first dosage unit or a second dosage unit). The cyclobenzaprine HCl of these methods is in the form of a mannitol eutectic (e.g., a 75% ± 2% by weight cyclobenzaprine HCl and 25% ± 2% by weight β‑mannitol eutectic) and the one or more dosage units further comprise a basifying agent.
Owner:TONIX PHARMA LTD

Methods and Kits for Determining Insulin Resistance Treatment

A method for determining whether an individual with prediabetes, AMIS, type 2 diabetes, gestational diabetes, insulin resistance, or impaired glucose tolerance will respond to a bethanechol and N-acetylcysteine treatment is taught. Blood samples are taken on a placebo day and on a test day. If the administration of bethanechol and N-acetylcysteine resulted in a reduced postprandial increase in glucose and insulin, this indicates that the drug could be beneficially used.
Owner:SCIMAR LTD

Treatment of asthma by blocking IL-13 and TSLP

The present invention provides compounds for use in the treatment of pulmonary diseases, particularly asthma, wherein the compounds bind to the cytokines IL-13 and TSLP. The treatment according to the invention is capable of reducing the level of exhaled nitric oxide (FeNO) by at least 18 ppb compared to placebo. The treatments of the invention are also capable of reducing eosinophil count, increasing FEV1 and / or reducing airway inflammation.
Owner:SANOFI SA(FR)

Machine learning (ML) model governance via placebo data injection validation

Aspects of the present disclosure relate to machine learning (ML) model governance. A first ML output can be received from a first version of a ML model based on a first prompt. The first version of the ML model can be trained on placebo data to obtain a second version of the ML model. A second ML output can be received from the second version of the ML model trained on the placebo data based on the first prompt. A validation result can be received based on a comparison between the first ML output and the second ML output.
Owner:INTERNATIONAL BUSINESS MACHINE CORPORATION

Naoxuekang dropping pill placebo as well as preparation method and application thereof

The invention relates to the technical field of medicines, and particularly discloses a Naoxuekang dropping pill placebo as well as a preparation method and application thereof. The Naoxuekang dropping pill placebo provided by the invention is prepared from the following components in parts by weight: 7000 to 13000 parts of matrix, 100 to 600 parts of pigment and 50 to 300 parts of compound essence, the matrix is polyethylene glycol; the pigment is caramel pigment; the compound essence is prepared by mixing propionic acid, isovaleric acid, 2-methylpyrazine, p-cresol, 2, 3-dimethylpyrazine, limonene and propylene glycol. The raw and auxiliary materials used in the application are safe, non-toxic and harmless, and the prepared Naoxuekang dropping pill placebo has high consistency with a tested raw medicine sample in the aspects of pill weight, appearance, color, smell, taste and other characters, and can be clinically used as a placebo.
Owner:BEIJING KANGERFU PHARMA CO LTD

Method and device for determining color scheme of traditional chinese medicine placebo, and placebo preparation method

The application provides a method and device for determining a color matching scheme of a traditional Chinese medicine placebo and a placebo preparation method. The method mainly comprises the following steps: providing color information of a target traditional Chinese medicine preparation to a pre-trained traditional Chinese medicine color clustering model to determine a corresponding clustering cluster of the target traditional Chinese medicine preparation, and selecting a color matching prediction model corresponding to the clustering cluster from a plurality of pre-trained color matching prediction models; and providing the extracted color information to the selected color matching prediction model to obtain a color matching scheme of a placebo corresponding to the target traditional Chinese medicine preparation. The solution of the application can more quickly and accurately obtain a color matching scheme of a traditional Chinese medicine placebo, thereby improving the preparation speed and efficiency of the traditional Chinese medicine placebo.
Owner:HAIHE LAB OF MODERN CHINESE MEDICINE +2

High-simulation placebo, preparation method thereof and application of high-simulation placebo in combined treatment of menopausal syndrome by traditional Chinese medicine and western medicine

The invention belongs to the technical field of medicines, and particularly provides a high-simulation placebo as well as a preparation method and application thereof in combined treatment of menopausal syndrome by traditional Chinese medicine and western medicine. The high-simulation placebo is prepared from the following components in parts by mass: caramel color, citrus yellow, citric acid, malic acid, raw medicine extract and the balance of maltodextrin. The high-simulation placebo is applied to a traditional Chinese and western medicine combined medication scheme, the unique advantages of western medicines and traditional Chinese medicines are deeply fused, and the weakness of a single therapy is ingeniously avoided. Western medicines can quickly relieve clinical symptoms of MPS patients by virtue of the characteristics of quick action and clear target spot; the traditional Chinese medicines have the effects of overall conditioning, mildness and durability, so that the body function of a patient is fundamentally improved, and the immunity is enhanced. The two components supplement each other, and the composition has obvious results in improvement of clinical symptoms of MPS patients and improvement of life quality, and can be clinically popularized.
Owner:THE AFFILIATED HOSPITAL OF TRADITIONAL CHINESE MEDICAL TO SOUTHWEST MEDICAL UNIV

Piracetam as a marker

The present invention relates to a composition for the consumption of a subject. The composition comprising piracetam as a monitoring marker for the composition and a substance. The substance is an active pharmaceutical ingredient (API), a placebo material, or a consumer substance. The present invention also relates to use of the composition and methods of monitoring a subject.
Owner:DI-ACETYLM BV

Methods for testing the non-inferiority of new drugs when efficacy data follow a skewed normal distribution

This application discloses a method for testing the non-inferiority of a new drug when efficacy data follows a skewed normal distribution. This method tests the non-inferiority of a new drug relative to a standard drug when efficacy data follows a skewed normal distribution, ensuring the reliability of the test results. S1. Acquisition of drug efficacy data in clinical trials: In a three-arm non-inferiority clinical trial, drug efficacy data are acquired from three groups of clinical trial results—the new drug group, the standard drug control group, and the placebo control group—based on drug efficacy indicators. The efficacy data follows a skewed normal distribution. S2. Calculation of the probability of committing a Type I error: In the three-arm non-inferiority hypothesis testing model, the probability of committing a Type I error is calculated using a frequentist method or a Bayesian method on the drug efficacy data from the three groups of trials. The probability of committing a Type I error is the probability of the alternative hypothesis H1 occurring when the null hypothesis H0 is true. S3. Determination of the non-inferiority of the new drug: If the probability of committing a Type I error is greater than a given reference value, the new drug is determined to be non-inferior to the standard drug. The reference value is a pre-given clinically significant threshold value.
Owner:KUNMING UNIV OF SCI & TECH

Method, system and equipment for generating placebo formula of traditional Chinese medicine compound decoction, medium and program product

The invention provides a method, a system and equipment for generating a placebo formula of a traditional Chinese medicine compound decoction, a medium and a program product. The generation method comprises the following steps: main control equipment determines a primary formula of the traditional Chinese medicine compound decoction placebo according to physical property parameters of to-be-selected components and appearance parameters of the traditional Chinese medicine compound decoction; the main control equipment instructs the test terminals to obtain reaction data of the test object for the primary selection formula to the test terminals, and based on the reaction data, a similarity result, an applicability result, a safety result and a controllability result of the primary selection formula are obtained; under the condition that the similarity result, the applicability result, the safety result and the controllability result of the primarily selected formula all meet the standard conditions of the medicament formula, the main control equipment determines that the primarily selected formula is the placebo formula of the traditional Chinese medicine compound decoction. According to the method for generating the placebo formula of the traditional Chinese medicine compound decoction, the production efficiency is improved, the quality of the placebo is guaranteed, and the placebo has good similarity, applicability, controllability and safety.
Owner:BEIJING UNIV OF CHINESE MEDICINE

Radix bupleuri liver soothing powder placebo as well as preparation method and evaluation method thereof

PendingCN120531899ACompounds screening/testingSolution deliveryChaihu-shugan-sanPlacebo
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a radix bupleuri liver soothing powder placebo as well as a preparation method and an evaluation method thereof. The placebo comprises a radix bupleuri liver soothing powder stock solution, pigment, dextrin, a flavoring agent, essence and a suspending aid. The placebo highly similar to the radix bupleuri liver soothing powder raw medicine is prepared by simulating color, clarity, taste and smell and combining with the optimization of a suspending aid. The placebo is suitable for clinical test control, and scientificity and reliability of test results are ensured.
Owner:XIYUAN HOSPITAL OF CHINA ACAD OF CHINESE MEDICAL SCI